Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
Werewolf Therapeutics, Inc. (HOWL)
Company Research
Source: GlobeNewswire
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and immunological diseases, today announced the appointment of Anil Singhal, Ph.D., President and Chief Executive Officer of Trishula Therapeutics, as a member of its board of directors. “I am thrilled to join Werewolf’s board of directors as the company advances its novel INDUKINE molecules through clinical development,” said Dr. Singhal. “Werewolf is demonstrating the power of the PREDATORTM protein engineering platform and its potential to provide safer and more efficacious treatments for cancer and immunological diseases.” “I am pleased to welcome Dr. Singhal to our board of directors at this exciting time for our company,” added Luke Evnin, Ph.D., Chairman of the Board of Directors and co-founder of W
Show less
Read more
Impact Snapshot
Event Time:
HOWL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOWL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOWL alerts
High impacting Werewolf Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOWL
News
- Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Citigroup Inc. from a "market outperform" rating to a "market perform" rating.MarketBeat
- Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $1.00 price target on the stock.MarketBeat
- Werewolf Therapeutics (NASDAQ:HOWL) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Werewolf Therapeutics Announces Pipeline and Business UpdatesGlobeNewswire
- Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
HOWL
Earnings
- 11/4/25 - Beat
HOWL
Sec Filings
- 12/18/25 - Form 8-K
- 12/17/25 - Form 4
- 12/12/25 - Form 4
- HOWL's page on the SEC website